The application of toxins and venoms to cardiovascular drug discovery

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 173-176

  Hodgson, Wayne C ^a   Isbister, Geoffrey K ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ATRIAL NATRIURETIC FACTOR; BRADYKININ POTENTIATING PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FISH VENOM; GLITAZONE DERIVATIVE; METFORMIN; NATRIURETIC PEPTIDE TYPE C; PEPTIDE DERIVATIVE; SARAFOTOXIN; SNAKE VENOM; SPIDER VENOM; SULFONYLUREA; TOXIN; UNCLASSIFIED DRUG; VENOM;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DRUG DESIGN; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; HUMANS; INCRETINS; NATRIURETIC PEPTIDES; OLIGOPEPTIDES; TOXINS, BIOLOGICAL; VIPER VENOMS;

EID: 62249085390     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.11.007     Document Type: Review

References (34)

1. Hodgson W.C., and Wickramaratna J.C. Snake venoms and their toxins: an Australian perspective. Toxicon 48 (2006) 931-940
2. Joseph R., Pahari S., Hodgson W.C., and Kini R.M. Hypotensive agents from snake venoms. Curr Drug Targets Cardiovasc Haematol Disord 4 (2004) 437-459
3. Fry B.G., Vidal N., Norman J.A., Vonk F.J., Scheib H., Ramjan R., Kuruppu S., Fung K., Hedges S.B., Richardson M.K., et al. Early evolution of the venom system in lizards and snakes. Nature 439 (2006) 584-588. The authors show that two additional lizard lineages possess venom apparatus and demonstrate a single early origin of the venom system in lizards and snakes.
4. Chen T., Kwok H.F., Ivanyi C., and Shaw C. Isolation and cloning of exendin precursor cDNAs from single samples of venom from Mexican beaded lizard (Heloderma horridum) and the Gila monster (Heloderma suspectum). Toxicon 47 (2006) 288-295
5. Ferreira S.H. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 24 (1965) 163-169
6. Conceição K., Konno K., Lopes de Melo R., Antoniazzi M.M., Jared C., Sciani J.M., Conceição I.M., Prezoto B.C., de Camargo A.C.M., and Pimenta A.M.C. Isolation and characterization of a novel bradykinin potentiating peptide (BPP) from the skin secretion of Phyllomedusa hypochondrialis. Peptides 28 (2007) 515-523
7. Gomes C.L., Konno K., Conceição I.M., Ianzer D., Yamanouye N., Prezoto B.C., Assakura M.T., Radis-Baptista G., Yamane T., Santos R.A., et al. Identification of novel bradykinin-potentiating peptides (BPPs) in the venom gland of a rattlesnake allowed the evaluation of the structure-function relationship of BPPs. Biochem Pharmacol 74 (2007) 1350-1360
8. Verano-Braga T., Rocha-Resende C., Silva D.M., Ianzer D., Martin-Eauclaire M.F., Bougis P.E., de Lima M.E., Santos R.A.S., and Pimenta A.M.C. Tityus serrulatus Hypotensins: a new family of peptides from scorpion venom. Biochem Biophys Res Comm 371 (2008) 515-520. The authors have identified four peptides displaying bradykinin-potentiating activity in the absence of ACE inhibition and appear to produce their anti-hypertensive activity via nitric oxide-dependent mechanisms.
9. Lee C.Y.W., and Burnett Jr. J.C. Natriuretic peptides and therapeutic applications. Heart Fail Rev 12 (2007) 131-142
10. Schweitz H., Vigne P., Moinier D., Frelin C., and Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the Green Mamba (Dendroaspis angusticeps). J Biol Chem 267 (1992) 13928-13932
11. St Pierre L., Flight S., Masci P.P., Hanchard K.J., Lewis R.J., Alewood P.F., de Jersey J., and Lavin M.F. Cloning and characterization of natriuretic peptides from the venom glands of Australian elapids. Biochimie 88 (2006) 1923-1931
12. Fry B.G., Wickramaratna J.C., Lemme S., Beuve A., Garbers D., Hodgson W.C., and Alewood P. Novel natriuretic peptides from the venom of the inland taipan (Oxyuranus microlepidotus): isolation, chemical and biological characterisation. Biochem Biophys Res Commun 327 (2005) 1011-1015
13. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., and Burnett Jr. J.C. Design, synthesis and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52 (2008) 60-68. The authors have created a chimeric natriuretic peptide with a pharmacological profile, which may be advantageous in the treatment of acute myocardial infarction and acute heart failure.
14. Iltz J.L., Baker D.E., Setter S.M., and Campbell R.K. Exenatide: an incretin mimetic for the treatment of Type 2 diabetes mellitus. Clin Ther 28 (2006) 652-665
15. Eng J., Kleinman W.A., Singh L., Singh G., and Raufman J.-P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267 (1992) 7402-7405
16. Parker D.S., Raufman J.-P., O'Donohue T.L., Bledsoe M., Yoshida H., and Pisano J.J. Amino acid sequences of helospectins, new members of the glucagon superfamily, found in Gila monster venom. J Biol Chem 259 (1992) 11751-11755
17. Vandermeers A., Vandermeers-Piret M.-C., Robberecht P., Waelbroeck M., Dehaye J.-P., Winand J., and Christophe J. Purification of a novel pancreatic secretory factor (PSF) and a novel peptide with VIP- and secretin-like properties (helodermin) from Gila monster venom. FEBS Lett 166 (1984) 273-276
18. Eng J., Andrews P.C., Kleinman W.A., Singh L., and Raufman J.-P. Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem 265 (1990) 20259-20262
19. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., Wintle M.E., and Maggs D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24 (2008) 275-286
20. Ducancel F. The sarafotoxins. Toxicon 40 (2002) 1541-1545
21. Kochva E., Viljoen C.C., and Botes D.P. A new type of toxin in the venom of snakes of the genus Atractaspis (Atractaspidinae). Toxicon 20 (1982) 581-592
22. Lauer-Fields J.L., Cudic M., Wei S., Mari F., Fields G.B., and Brew K. Engineered sarafotoxins as tissue inhibitor of metalloproteinases-like matrix metalloproteinase inhibitors. J Biol Chem 282 (2007) 26948-26955. The authors have synthesized a peptide, which inhibits matrix metalloproteinase-1 and metalloproteinase-9. It is hoped that this work will provide a framework for the development of further candidate molecules.
23. Bode F., Sachs F., and Franz M.R. Tarantula peptide inhibits atrial fibrillation. Nature 409 (2001) 35-36
24. Estrada G., Villegas E., and Corzo G. Spider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs. Nat Prod Rep 24 (2007) 145-161
25. Xiao Y., Tang J., Hu W., Xie J., Maertens C., Tytgat J., and Liang S. Jingzhaotoxin-I, a novel spider neurotoxin preferentially inhibiting cardiac sodium channel inactivation. J Biol Chem 280 (2005) 12069-12076
26. Church J.E., and Hodgson W.C. The pharmacological activity of fish venoms. Toxicon 40 (2002) 1083-1093
27. Ramasamy S., Isbister G.K., Seymour J.E., and Hodgson W.C. The in vivo cardiovascular effects of box jellyfish Chironex fleckeri venom in rats: efficacy of pre-treatment with antivenom, verapamil and magnesium sulphate. Toxicon 43 (2004) 685-690
28. Ramasamy S., Isbister G.K., Seymour J.E., and Hodgson W.C. The in vivo cardiovascular effects of the Irukandji jellyfish (Carukia barnesi) nematocyst venom and a tentacle extract in rats. Toxicol Lett 155 (2005) 135-141
29. Winter K.L., Fernando R., Ramasamy S., Seymour J.E., Isbister G.K., and Hodgson W.C. The in vitro vascular effects of two chirodropid (Chironex fleckeri and Chiropsella bronzie) venoms. Toxicol Lett 168 (2007) 13-20
30. Winter K.L., Isbister G.K., Schneider J.J., Konstantakopoulos N., Seymour J.E., and Hodgson W.C. An examination of the cardiovascular effects of an 'Irukandji' jellyfish Alatina nr mordens. Toxicol Lett 179 (2008) 118-123
31. Brinkman D., and Burnell J. Identification, cloning and sequencing of two major venom proteins from the box jellyfish, Chironex fleckeri. Toxicon 50 (2007) 850-860. The authors have identified the structures of two toxins (i.e. CfTX-1 and CfTX-2) with a transmembrane spanning region indicative of pore-forming toxins.
32. Brinkman D., and Burnell J. Partial purification of cytolytic venom proteins from the box jellyfish, Chironex fleckeri. Toxicon 51 (2008) 853-863
33. Nagai H., Takuwa K., Nakao M., Ito E., Miyake M., Noda M., and Nakajima T. Novel proteinaceous toxins from the box jellyfish (sea wasp) Carybdea rastoni. Biochem Biophys Res Commun 275 (2000) 582-588
34. Nagai H., Takuwa-Kuroda K., Nakao M., Oshiro N., Iwanaga S., and Nakajima T. A novel protein toxin from the deadly box jellyfish (Sea Wasp, Habu-kurage) Chiropsalmus quadrigatus. Biosci Biotechnol Biochem 66 (2002) 97-102